The diagnostic potential of Golgi protein 73 for cirrhosis in patients with chronic hepatitis C.
10.3760/cma.j.cn501113-20200415-00186
- Author:
Peng Fei WANG
1
;
Shu Hong LIU
2
;
Xiang Jun QIAN
3
;
Xiang Wei ZHAI
1
;
Xia Jie WEN
3
;
Ming Jie YAO
4
;
Jing Min ZHAO
2
;
Fengmin LU
5
Author Information
1. Department of Epidemiology and Statistics, College of Public Health Zhengzhou University, Zhengzhou 450001, China.
2. Fifth Medical Center of Chinese PLA General Hospital,Beijing 100039, China.
3. Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
4. Department of Human Anatomy and Histology and Embryology, School of Basic Medicine, Peking University, Beijing 100191, China.
5. Department of Epidemiology and Statistics, College of Public Health Zhengzhou University, Zhengzhou 450001, China Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
- Publication Type:Journal Article
- MeSH:
Aspartate Aminotransferases;
Biomarkers;
Fibrosis;
Hepatitis C;
Hepatitis C, Chronic/complications*;
Humans;
Infant, Newborn;
Liver/pathology*;
Liver Cirrhosis/pathology*;
Polyesters;
ROC Curve;
Retrospective Studies
- From:
Chinese Journal of Hepatology
2022;30(8):879-884
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the diagnostic value and model of serum Golgi protein 73 (GP73) in patients with hepatitis C cirrhosis. Methods: 271 cases with chronic hepatitis C virus infection who were treated in the Fifth Medical Center of PLA General Hospital from January 2010 to December 2017 were retrospectively collected as the research objects, including 126 cases with hepatitis and 145 cases with liver cirrhosis. Serum GP73 and liver stiffness measurement (LSM) based on transient elastography test were performed in all patients. Simultaneously, blood routine, liver function, coagulation function and other related indicators were collected. GP73 diagnostic efficiency for liver cirrhosis was evaluated by receiver operating characteristic curve (ROC). GP73 diagnostic value was clarified after comparison with aspartate aminotransferase/platelet ratio index (APRI), FIB-4 index (FIB-4) and LSM. Compensated hepatitis C virus-related cirrhosis diagnostic model based on serological index was established by logistic regression analysis. Results: The area under the receiver operating characteristic curve (AUC) of GP73, LSM, FIB-4 and APRI in the diagnosis of compensated hepatitis C virus-related cirrhosis were 0.923, 0.839, 0.836 and 0.800 respectively, and GP73 had the best diagnostic efficiency (P <0.001). LSM and GP73 combined use had improved the diagnostic sensitivity of cirrhosis to 97.24%. Multivariate logistic regression analysis revealed that GP73, age, and platelets were independent predictors of cirrhosis.Compensated hepatitis C virus-related cirrhosis diagnostic model (GAP) was established based on the result: LogitP=1/[1+exp(6.145+0.013×platelet-0.059×age-0.059×GP73)].AUC model for diagnosing compensated liver cirrhosis was 0.944, and the optimal cut-off value was 0.56, with sensitivity and specificity of 84.03% and 92.06%, respectively, and the diagnostic efficiency of this model was better than that of APRI, FIB-4, LSM and GP73 alone (P<0.05). Conclusion: GP73 is a reliable serum biomarker for the diagnosis of compensated hepatitis C virus-related cirrhosis. The GAP diagnostic model based on GP73, platelet count, and age can further improve the diagnostic efficiency and help to diagnose patients with compensated hepatitis C virus-related cirrhosis.
